- Report
- October 2024
- 182 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 183 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- August 2024
- 203 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- February 2025
- 72 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- August 2022
- 34 Pages
Global
From €1288EUR$1,350USD£1,080GBP
- Report
- March 2024
- 132 Pages
Global
From €907EUR$950USD£760GBP
The Apoptosis Assay market within the context of Oncology Drugs is a specialized field of research that focuses on the study of programmed cell death. Apoptosis assays are used to measure the efficacy of oncology drugs in inducing apoptosis, or cell death, in cancer cells. These assays are used to evaluate the effectiveness of oncology drugs in killing cancer cells, as well as to identify potential side effects of the drugs. Apoptosis assays are also used to study the mechanisms of action of oncology drugs, and to identify biomarkers that can be used to predict drug response.
Some companies in the Apoptosis Assay market within the context of Oncology Drugs include Bio-Rad Laboratories, Promega Corporation, Merck KGaA, Cell Signaling Technology, Inc., and Abcam plc. Show Less Read more
